Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
01:32am, Thursday, 08'th Aug 2024
Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and
Is Recursion Pharmaceuticals a Millionaire-Maker?
06:00am, Tuesday, 06'th Aug 2024
Recursion could have three different revenue streams one day. Right now, it only has one but another may soon be within reach.
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
04:01pm, Monday, 05'th Aug 2024
Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why
06:56pm, Monday, 29'th Jul 2024
Recursion Pharmaceuticals (RXRX) closed at $8.19 in the latest trading session, marking a -1.92% move from the prior day.
Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?
05:41am, Saturday, 27'th Jul 2024
Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.
Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know
10:55am, Friday, 26'th Jul 2024
The consensus price target hints at a 43.7% upside potential for Recursion Pharmaceuticals (RXRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
3 Millionaire-Maker Artificial Intelligence (AI) Stocks
06:10am, Thursday, 18'th Jul 2024
Voice-based communications with computers is pretty basic. SoundHound AI allows this communication to be more complex as well as more interactive.
Is Recursion Pharmaceuticals Stock a Buy?
06:25am, Sunday, 14'th Jul 2024
Recursion Pharmaceuticals wants to disrupt drug development. It's leaning on new information technology and automation methods.
1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell
09:29am, Saturday, 13'th Jul 2024
Recursion Pharmaceuticals is looking to revolutionize the drug development process. The biotech's strategy has yet to deliver major medical breakthroughs.
3 Healthcare Stocks Injecting AI for Big Gains
06:26am, Saturday, 13'th Jul 2024
While the pairing of artificial intelligence and healthcare may sound like something straight out of a science fiction movie, there are several avenues through which the high-speed data processing off
These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street
05:50am, Friday, 12'th Jul 2024
Nano-X Imaging is especially popular with analysts. Recursion Pharmaceuticals plans to report results from seven clinical studies over the next 18 months.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:50am, Thursday, 11'th Jul 2024
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
07:09pm, Monday, 08'th Jul 2024
The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.
3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030
09:12am, Wednesday, 03'rd Jul 2024
Amazon (NASDAQ: AMZN ) has more skin in the AI game than many people would like to think. Of course, the first thing that would spring to mind is the company's AWS cloud division.
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn't Discovered Yet
10:28am, Friday, 28'th Jun 2024
Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various clinical tri
